Answers are grounded in this paper and cite their sources.
Nirmatrelvir, the novel antiviral component of Pfizer’s orally available combination therapy Paxlovid, used to treat COVID-19, presents a significant synthetic challenge. Herein, we report process optimization insights that could enable a scalable and cost-effective manufacturing process to make nirmatrelvir. The disclosed development opens up a path to three new complete routes, offering options to eliminate some of the major cost-drivers for nirmatrelvir and deliver the final API in higher yield and lower overall cost while maintaining quality requirements.
No takes yet. Share an insight, caveat, or question.
Shanahan et al. (2022) studied this question.